Blog
RSS FeedPosted by Michael Wonder on 13 Jul 2022
ICER releases draft evidence report on treatments for obesity management
13 July 2022 - Registration now open for 26 July “Early Insights” webinar. ...
Posted by Michael Wonder on 11 Jul 2022
ICER launches initiative to evaluate and advance health technology assessment methods that support health equity
11 July 2022 - Funding from Commonwealth Fund supports a broad based initiative exploring potential changes in all health technology assessment ...
Posted by Michael Wonder on 14 Jun 2022
ICER releases draft evidence report on treatments for amyotrophic lateral sclerosis
14 June 2022 - Public comment period now open until 13 July 2022; requests to make oral comment during public ...
Posted by Michael Wonder on 02 Jun 2022
ICER publishes evidence report on gene therapy for beta thalassaemia
2 June 2022 - Evidence judged to demonstrate that beti-cel provides net health benefit to patients with transfusion-dependent thalassaemia. ...
Posted by Michael Wonder on 01 Jun 2022
ICER to assess treatment for vasomotor symptoms associated with menopause
1 June 2022 - Report will be subject of Midwest CEPAC meeting in December 2022; draft scoping document open to ...
Posted by Michael Wonder on 10 May 2022
ICER publishes final evidence report and policy recommendations on outpatient treatments for COVID-19
10 May 2022 - Independent appraisal committee votes 11-2 that the evidence is not adequate to demonstrate a net health benefit ...
Posted by Michael Wonder on 05 May 2022
ICER to assess gene therapies for haemophilia A and B
5 May 2022 - Report will be subject of CTAF meeting in November 2022; draft scoping document open to public ...
Posted by Michael Wonder on 05 May 2022
ICER’s favourable assessment of Bluebird Bio’s gene therapy Zynteglo may have important pricing and reimbursement implications
5 May 2022 - ICER evaluated the clinical and cost-effectiveness - as well as budgetary impact - of one of two ...
Posted by Michael Wonder on 21 Apr 2022
ICER to assess treatments for multiple sclerosis
21 April 2022 - Report will be subject of New England CEPAC meeting in January 2023; draft scoping document open ...
Posted by Michael Wonder on 14 Apr 2022
ICER publishes 2022 research protocol for assessing unsupported price increases on prescription drugs
14 April 2022 - Final assessment to be published on 6 December 2022. ...
Posted by Michael Wonder on 13 Apr 2022
ICER releases draft evidence report on gene therapy for beta thalassaemia
13 April 2022 - Public comment period now open until 10 May 2022; requests to make oral comment during public ...
Posted by Michael Wonder on 07 Apr 2022
ICER publishes white paper evaluating reforms to orphan drug development, pricing and coverage
7 April 2022 - The white paper presents an analysis of the potential risks and benefits of reforms seeking to ...
Posted by Michael Wonder on 28 Mar 2022
ICER publishes evidence report on treatments for COVID-19
28 March 2022 - Current evidence suggests all four drugs under review have prices reasonably aligned with patient benefits. ...
Posted by Michael Wonder on 17 Mar 2022
ICER publishes evidence report on novel agents to prevent chemotherapy-induced neutropenia and other myelosuppressive effects
17 March 2022 - Due to the FDA action on plinabulin, ICER will not hold a public meeting but has produced ...
Posted by Michael Wonder on 16 Mar 2022
ICER publishes research protocol for assessing price increases of prescription drugs in California
16 March 2022 - Final assessment to be published on 13 October; drugs to be evaluated are those identified through California’s ...